Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.
News & Analysis: Alector
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?